SYT11 Gene Marker Panel for Diffuse Gastric Cancer Prognosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for diffuse type gastric cancer are inadequate, particularly in early detection and prognosis, and there is a lack of markers for predicting the effectiveness of therapeutic agents.

Innovation Solution

A composition and kit for diagnosing and predicting the prognosis of diffuse type gastric cancer using the SYT11 gene and additional markers such as ANGPTL2, CACNB1, CCL19, CD34, JAM3, SLIT2, THBS4, and VIMENTIN, along with methods for measuring gene expression levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If physical diagnostic methods such as X-ray radiography or gastroscopy are used, then gastric cancer can be detected, but the process is painful for patients and requires cumbersome procedures

Engineering Contradiction:

Improvedetection capabilityVSAvoidpatient comfort and procedural simplicity

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces mechanical/physical diagnostic methods (gastroscopy, X-ray) with a biochemical detection system that measures gene expression levels in tissue samples. This substitution eliminates the need for invasive physical procedures while maintaining diagnostic capability through molecular biology techniques.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing gastric cancer markers are measured, then diagnosis can be performed, but there is insufficient research on markers specifically for diffuse type gastric cancer prognosis

Engineering Contradiction:

Improvediagnostic capabilityVSAvoidprognosis information for diffuse type

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent identifies specific genes (SYT11, ANGPTL2, CACNB1, CCL19, CD34, JAM3, SLIT2, THBS4, VIMENTIN) that are differentially expressed in diffuse type gastric cancer compared to other types. This localizes the diagnostic approach to specific molecular characteristics of diffuse type cancer, providing tailored prognosis information rather than using general gastric cancer markers.

Inventive Principle:

Principle #3Local quality

3Productivity

If SYT11 targeted therapeutic agents are administered, then treatment can be provided, but there is no research on marker genes to predict treatment effectiveness in advance

Engineering Contradiction:

Improvetreatment deliveryVSAvoidpredictive information for therapeutic strategy

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent performs preliminary measurement of gene expression levels (particularly SYT11 and associated markers) before administering SYT11 targeted therapeutic agents. This preliminary action provides predictive information about treatment effectiveness, allowing clinicians to establish appropriate therapeutic strategies in advance rather than trial-and-error treatment approaches.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260110036A1Marker for prognosis of diffuse type gastric cancer and treatment target

Publication Date: 2026.04.23 KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY

AI summary

The present disclosure provides a composition and a kit for diagnosis or prognosis of diffuse type gastric cancer, each including an agent for measuring an expression level of SYT11 gene. Also provided in the present disclosure is a method for providing information necessary for the diagnosis of diffuse type gastric cancer or for determining a therapeutic strategy for diffuse type gastric cancer.